State of New Jersey Common Pension Fund D Boosts Holdings in Haemonetics Co. (NYSE:HAE)

State of New Jersey Common Pension Fund D raised its holdings in Haemonetics Co. (NYSE:HAE) by 22.0% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 25,932 shares of the medical instruments supplier’s stock after purchasing an additional 4,672 shares during the period. State of New Jersey Common Pension Fund D owned 0.05% of Haemonetics worth $2,084,000 at the end of the most recent reporting period.

Other large investors have also modified their holdings of the company. ProShare Advisors LLC boosted its stake in shares of Haemonetics by 4.7% during the first quarter. ProShare Advisors LLC now owns 11,490 shares of the medical instruments supplier’s stock valued at $981,000 after acquiring an additional 516 shares during the last quarter. State Board of Administration of Florida Retirement System grew its holdings in shares of Haemonetics by 15.1% during the first quarter. State Board of Administration of Florida Retirement System now owns 16,475 shares of the medical instruments supplier’s stock worth $1,363,000 after buying an additional 2,160 shares in the last quarter. Edgestream Partners L.P. acquired a new position in shares of Haemonetics in the first quarter valued at approximately $1,723,000. Covestor Ltd raised its position in shares of Haemonetics by 184.8% in the first quarter. Covestor Ltd now owns 675 shares of the medical instruments supplier’s stock valued at $58,000 after buying an additional 438 shares during the last quarter. Finally, CANADA LIFE ASSURANCE Co lifted its stake in shares of Haemonetics by 13.2% during the first quarter. CANADA LIFE ASSURANCE Co now owns 50,728 shares of the medical instruments supplier’s stock valued at $4,330,000 after buying an additional 5,933 shares during the period. 99.67% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several research analysts have weighed in on the company. JMP Securities reiterated a “market outperform” rating and issued a $125.00 price target on shares of Haemonetics in a report on Tuesday, August 13th. Citigroup decreased their price target on Haemonetics from $94.00 to $85.00 and set a “neutral” rating on the stock in a research note on Thursday, August 22nd. BTIG Research assumed coverage on shares of Haemonetics in a research note on Tuesday, September 10th. They set a “buy” rating and a $112.00 price objective for the company. Needham & Company LLC reissued a “buy” rating and issued a $112.00 target price on shares of Haemonetics in a research report on Friday. Finally, Raymond James raised shares of Haemonetics from an “outperform” rating to a “strong-buy” rating and set a $120.00 price target for the company in a research report on Friday, November 8th. Three equities research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $107.88.

Haemonetics Stock Down 1.7 %

Shares of NYSE:HAE opened at $89.24 on Friday. The company has a market capitalization of $4.48 billion, a price-to-earnings ratio of 37.01, a price-to-earnings-growth ratio of 1.43 and a beta of 0.32. The company has a 50 day moving average of $77.23 and a two-hundred day moving average of $82.77. Haemonetics Co. has a 52-week low of $70.25 and a 52-week high of $97.97. The company has a quick ratio of 2.09, a current ratio of 3.49 and a debt-to-equity ratio of 1.39.

Haemonetics (NYSE:HAE) last released its quarterly earnings results on Thursday, November 7th. The medical instruments supplier reported $1.12 earnings per share for the quarter, beating analysts’ consensus estimates of $1.09 by $0.03. Haemonetics had a net margin of 9.10% and a return on equity of 22.67%. The business had revenue of $345.50 million during the quarter, compared to analyst estimates of $342.57 million. During the same period last year, the business earned $0.99 EPS. The business’s revenue was up 8.6% on a year-over-year basis. As a group, analysts forecast that Haemonetics Co. will post 4.59 earnings per share for the current fiscal year.

About Haemonetics

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.